Your session is about to expire
← Back to Search
Neoadjuvant Lenvatinib + Pembrolizumab for Kidney Cancer
Study Summary
This trialwill study a new cancer treatment to see if it is safe and effective for treating kidney cancer with blockage in the veins.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had radiotherapy less than 2 weeks before starting the study treatment.Your heart takes too long to recharge between beats.I am a male and agree to use approved birth control methods for 90 days after my last treatment dose and not donate sperm.I have not received a live vaccine in the last 30 days.I am highly allergic to pembrolizumab, lenvatinib, or their ingredients.My organs are functioning well.I have had serious heart problems in the last year.I have received an organ or tissue transplant from another person.You have more than 1 gram of protein in your urine over a 24-hour period.I have no health issues that could affect the study's results.I have been treated for an autoimmune disease in the last 2 years.My doctor thinks my tumor and related blood clot can or cannot be surgically removed.I have provided a sample of my tumor that has not been treated with radiation.I have had cancer treatment, including experimental drugs, before.You have a disease that can be measured using a specific medical guideline.I am fully active or can carry out light work.My kidney cancer has spread to more than three places.I have active brain metastases or cancer in the lining of my brain.Your kidney function needs to be checked as per the hospital's usual method.Your heart's pumping ability is below the normal range.I have an immune system disorder or have been on steroids or other immune-weakening drugs in the last week.I have another cancer that is getting worse or was treated in the last year.I have had or currently have lung inflammation treated with steroids.I am currently being treated for an infection.My blood pressure is high despite taking medication.My kidney cancer is advanced, affecting nearby veins but not beyond.I am 18 years old or older.I haven't had a blood transfusion or needed erythropoietin in the last 2 weeks.I am not pregnant, not breastfeeding, and follow specific birth control methods.I have been treated with specific medications before.
- Group 1: Treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any risks associated with Treatment Arm for participants?
"As this experimental arm is only in Phase 2 with limited data on efficacy, its safety rating stands at a 2."
What is the primary goal of this scientific experiment?
"This clinical trial intends to measure Disease Control Rate across 12 weeks. Additionally, the evaluation of Intra-operative complications, Estimated blood loss and Survival Outcomes will be used as secondary objectives for this study."
Are there any vacancies within this trial for individuals to join?
"Affirmative, the information on clinicaltrials.gov suggests that this medical trial is presently searching for eligible candidates. This study was initially revealed on January 6th 2023 and underwent its most recent update February 6th of the same year. The team requires 30 individuals to be enrolled at one site."
How many individuals are currently enrolled in this clinical experiment?
"Affirmative. Clinicaltrials.gov's data implies that this clinical trial is currently recruiting individuals. The study was initially posted on June 1st 2023 and had its most recent update on June 2nd 2023, with the objective of enrolling thirty patients at one site."
Share this study with friends
Copy Link
Messenger